British scientists may have found a way to distinguish deadly forms of prostate cancer from relatively harmless ones, it was announced last night.
Researchers said they had found a protein, found in high levels in aggressive prostate cancer and also when it had spread around the body.
The protein NAALADL2 can be used to diagnose cancer – but also can be measured to assess how dangerous the cancer is, according to the study.
Researchers, from Cambridge University, UK, said the finding was an "important step" towards finding a test to distinguish between different kinds of prostate cancer.
The findings, published in the journal Oncogene, came from an analysis of two separate groups of patients.
Researcher Dr Hayley Whitaker said: “This is early research, but if clinical trials confirm our results then it could help clinicians to tell which patients have a more aggressive tumour and need proportionally aggressive treatment, while sparing patients with low grade tumours unnecessary radiotherapy or surgery.
“This is an important step along the path to developing a much-sought after test that could distinguish between different types of prostate cancer."
Professor Malcolm Mason, of Cardiff University, who advises Cancer Research UK, which funded the research, said the findings were "extremely interesting."
He said: "As a prostate cancer clinician, I have been waiting for years for a test that can define the aggressive disease.
"I hope that this research brings forward the day when I can say to patients: ‘We know that your cancer doesn’t need treatment’ – a crucial development that could spare thousands of patients from enduring arduous treatment with unpleasant side effects."
Neal et al. N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is over expressed in cancer and promotes a pro-migratory and pro-metastatic phenotype. Oncogene 18 November 2013

Leave a Reply